(Q37686610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Population-based differences in treatment outcome following anticancer drug therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Tony Mok

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Edwin P Hui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

75-84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of lung cancer: looking to the future.

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Smoking-adjusted lung cancer incidence among Asian-Americans (United States).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Lung cancer rates in men and women with comparable histories of smoking

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Emerging ethnic differences in lung cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Trends in breast cancer by race and ethnicity: update 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Ethnicity and breast cancer: factors influencing differences in incidence and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Neutropenia in 6 ethnic groups from the Caribbean and the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Explaining black-white differences in receipt of recommended colon cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Characterization of the human dihydropyrimidine dehydrogenase gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

The decreasing burden of gastric cancer in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Survival of patients with oesophageal and gastric cancers in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Sex as a prognostic factor in gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Disparities in gastric cancer chemotherapy between the East and West

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Incidence and mortality from stomach cancer in Japan, Slovenia and the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Irinotecan pharmacogenetics: influence of pharmacodynamic genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Pharmacogenetics and irinotecan therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970160-3

7 January 2021

10.1016/S1470-2045(09)70160-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20129130%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference